US Broker Ratings

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: Navigating a 55.66% Potential Upside in Biotech

For investors with an eye on the biotechnology sector, Praxis Precision Medicines, Inc (NASDAQ: PRAX) presents an intriguing opportunity. With a market capitalization of $6.73 billion, this Boston-based clinical-stage biopharmaceutical..

KalVista Pharmaceuticals, Inc. (KALV): Analyst Consensus Reveals Over 100% Potential Upside

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a burgeoning name in the biotechnology sector, is capturing investor attention with its innovative approach to addressing unmet medical needs. Specializing in the discovery and..

Bicycle Therapeutics plc (BCYC) Stock Analysis: Exploring a 217.58% Potential Upside

Bicycle Therapeutics plc (BCYC), a UK-based biotechnology firm, is making waves in the healthcare sector with its innovative therapeutic solutions aimed at addressing diseases lacking effective treatments. With a market..

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Exploring a 239% Upside Potential in Innovative Cancer Therapies

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a company at the forefront of biotechnology, is capturing the attention of investors with its promising therapies targeting metastatic melanoma and other solid tumors. With..

Eton Pharmaceuticals (ETON) Investor Outlook: Exploring an 87% Potential Upside in the Rare Disease Market

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is capturing investor attention with its robust growth potential in the niche market of rare disease treatments. With a market capitalization of $429.62 million, this..

Bicara Therapeutics Inc. (BCAX) Stock Analysis: Unpacking the 84.65% Potential Upside for Investors

In the ever-evolving landscape of biotechnology, Bicara Therapeutics Inc. (NASDAQ: BCAX) emerges as a compelling player with substantial growth potential. With a market capitalization of $966.35 million, this clinical-stage biopharmaceutical..

GH Research PLC (GHRS) Stock Analysis: Exploring a 138.80% Upside in the Biotech Sector

GH Research PLC (NASDAQ: GHRS), a Dublin-based biopharmaceutical company, is making waves in the healthcare sector with its innovative approach to treating depression. The company’s focus on developing novel treatments..

Xencor, Inc. (XNCR) Investor Outlook: An 80% Upside Potential in the Biotech Frontier

Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company based in Pasadena, California, is capturing the attention of investors with a potential upside of 80.05%, according to current analyst ratings. With a..

Pharvaris N.V. (PHVS) Stock Analysis: Potential Upside of Over 90% Beckons Investors

Pharvaris N.V. (PHVS), a biopharmaceutical entity based in Zug, Switzerland, is making waves in the healthcare sector with its pioneering approach to treating rare diseases such as hereditary angioedema (HAE)...

Sionna Therapeutics, Inc. (SION) Stock Analysis: Strong Buy Ratings Amidst Promising Cystic Fibrosis Pipeline

Sionna Therapeutics, Inc. (SION), a burgeoning player in the biotechnology sector, has captured the attention of investors with its promising pipeline focused on cystic fibrosis treatments. Despite the challenges typical..

Embecta Corp. (EMBC) Stock Analysis: Exploring a 42% Potential Upside in the Healthcare Sector

Embecta Corp. (NASDAQ: EMBC), a prominent player in the healthcare sector, specializes in medical instruments and supplies, focusing on diabetes management solutions. Despite operating in a challenging market, Embecta presents..

SI-BONE, Inc. (SIBN) Stock Analysis: A Robust 27.85% Potential Upside Beckons Investors

SI-BONE, Inc. (NASDAQ: SIBN) is making waves in the healthcare sector, specifically within the medical devices industry, with a strong focus on innovative solutions for musculoskeletal disorders. This Santa Clara-based..

Arcus Biosciences, Inc. (RCUS) Stock Analysis: Unveiling a 45.98% Upside Potential Amidst Clinical Innovations

Arcus Biosciences, Inc. (NASDAQ: RCUS), a trailblazer in the biotechnology sector, holds a promising position in the healthcare industry with a market capitalization of $2.72 billion. This clinical-stage biopharmaceutical company,..

RxSight, Inc. (RXST) Stock Analysis: Navigating a -16.06% Potential Downside with Innovative Technology

RxSight, Inc. (NASDAQ: RXST), a prominent player in the healthcare sector, specifically within the medical devices industry, is attracting attention due to its innovative approach to cataract surgery. The company’s..

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Strong Revenue Growth and Promising Analyst Ratings

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) has been making waves in the healthcare sector, particularly within the drug manufacturing industry specializing in both specialty and generic formulations. With a robust market..

uniQure N.V. (QURE) Stock Analysis: Unveiling a 131% Potential Upside in the Biotech Sector

In the dynamic landscape of biotechnology, uniQure N.V. (NASDAQ: QURE) stands out with an impressive potential upside of 131.20%, making it an intriguing prospect for investors with an eye on..

Immunome, Inc. (IMNM) Stock Analysis: Unveiling a 71.68% Upside Potential in the Fast-Paced Biotech Sector

Immunome, Inc. (NASDAQ: IMNM) is capturing the attention of investors with its promising position in the biotechnology industry. Specializing in the development of targeted cancer therapies, Immunome is currently a..

Maravai LifeSciences Holdings (MRVI) Stock Analysis: An 11.61% Upside in the Biotech Sector

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) has caught the attention of investors with its significant 11.61% potential upside, as reflected by the average analyst price target of $3.93. In the..

CeriBell, Inc. (CBLL) Stock Analysis: 31.82% Upside Potential and Strong Buy Ratings

CeriBell, Inc. (NASDAQ: CBLL), a medical technology company at the forefront of neurological patient care, is turning heads in the healthcare sector. With its innovative approach to diagnosing and managing..

Spyre Therapeutics (SYRE) Stock Analysis: Uncovering a 62.49% Potential Upside in Biotechnology

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, has been capturing investor attention with its ambitious pipeline targeting inflammatory bowel disease (IBD). With a market..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds